Toggle Main Menu Toggle Search

Open Access padlockePrints

Metabolic profiling of Parkinson's disease and mild cognitive impairment

Lookup NU author(s): Dr Florence Burte, Dr Dave Houghton, Hannah Lowes, Dr Angela Pyle, Sarah Nesbitt, Professor Alison Yarnall, Dr Patrick Yu Wai Man, Professor David Burn, Dr Mauro Santibanez Koref, Professor Gavin Hudson



This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


© 2017 International Parkinson and Movement Disorder Society. Background: Early diagnosis of Parkinson's disease and mild cognitive impairment is important to enable prompt treatment and improve patient welfare, yet no standard diagnostic test is available. Metabolomics is a powerful tool used to elucidate disease mechanisms and identify potential biomarkers. Objectives: The objective of this study was to use metabolic profiling to understand the pathoetiology of Parkinson's disease and to identify potential disease biomarkers. Methods: This study compared the serological metabolomic profiles of early-stage Parkinson's patients (diagnosed<12 months) to asymptomatic matched controls using an established array based detection system (DiscoveryHD4™, Metabolon, UK), correlating metabolite levels to clinical measurements of cognitive impairment. Results: A total of 1434 serological metabolites were assessed in early-stage Parkinson's disease cases (n=41) and asymptomatic matched controls (n=40). Post-quality control, statistical analysis identified n=20 metabolites, predominantly metabolites of the fatty acid oxidation pathway, associated with Parkinson's disease and mild cognitive impairment. Receiver operator curve assessment confirmed that the nine fatty acid oxidation metabolites had good predictive accuracy (area under curve=0.857) for early-stage Parkinson's disease and mild cognitive impairment (area under curve=0.759). Conclusions: Our study indicates that fatty acid oxidation may be an important component in the pathophysiology of Parkinson's disease and may have potential as a diagnostic biomarker for disease onset and mild cognitive impairment.

Publication metadata

Author(s): Burte F, Houghton D, Lowes H, Pyle A, Nesbitt S, Yarnall A, Yu-Wai-Man P, Burn DJ, Santibanez-Koref M, Hudson G

Publication type: Article

Publication status: Published

Journal: Movement Disorders

Year: 2017

Volume: 32

Issue: 6

Pages: 927–932

Print publication date: 08/06/2017

Online publication date: 10/04/2017

Acceptance date: 25/02/2017

Date deposited: 10/05/2017

ISSN (print): 0885-3185

ISSN (electronic): 1531-8257

Publisher: John Wiley and Sons Inc.


DOI: 10.1002/mds.26992


Altmetrics provided by Altmetric


Funder referenceFunder name
F-1202Parkinson`s UK (formerly Parkinson`s Disease Society)